For example, glioma cells secrete EVs that carry the epidermal growth factor receptor variant III (EGFRvIII), and prostate cancer cells secrete EVs that express trophoblast cell‐surface antigen 2 (Trop‐2), and such EVs may deliver their cargo into cancer cells within the same tumour that lack EGFRvIII or Trop‐2 expression (Al‐Nedawi et al., 2008; Trerotola et al., 2015). Here, TACSTD2 is linked to prostate carcinoma.